Sarepta Therapeutics, Inc. SRPT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $730.8M+65.0% | $442.93M+10.9% | $399.36M-34.6% | $611.09M-18.0% | $744.86M— | ||
| $29.4M— | —— | $14.9M-59.7% | $37M-10.6% | $41.4M— | ||
| $10.59M+102% | $5.25M-71.5% | $18.45M+70.2% | $10.84M+8.6% | $9.98M-4.6% | ||
| $330.96M+217% | -$282.85M-57.2% | -$179.95M— | —— | -$447.51M-381% | ||
| 45.3%+109pp | -63.9%-18.8pp | -45.1%— | —— | -60.1%— | ||
| $29.4M— | —— | $14.9M-59.7% | $37M-10.6% | $41.4M— | ||
| $6.93M-4.4% | $7.25M+79.4% | $4.04M-41.6% | $6.93M-4.9% | $7.29M-6.8% | ||
| $1.73M-89.5% | $16.38M+1,317% | $1.16M-94.0% | $19.26M+2,206% | $835K-92.4% | ||
| -$3.42M— | $0+100% | -$131.56M+0.4% | -$132.08M-330% | $57.38M-65.7% | ||
| $69.76M— | $0-100% | $83.02M+40.3% | $59.19M-66.6% | $177.36M+9.7% | ||
| $14.55M— | —— | $62.81M+183% | $22.19M+47.3% | $15.07M— | ||
| $23.42M+2,363% | $951K-86.0% | $6.77M— | $0-100% | $7.19M+946% | ||
| $241K+101% | -$39.21M+66.7% | -$117.79M-395% | -$23.82M-291% | $12.47M-74.5% | ||
| -$134.39M-240% | $96.21M— | —— | —— | -$291.18M-138% | ||
| -$202.68M— | —— | -$14.59M— | —— | -$583.44M— | ||
| $1.29M+149% | -$2.62M-130% | -$1.14M+60.3% | -$2.87M-69.3% | -$1.69M— | ||
| $170.2M— | —— | —— | —— | $44.66M-72.6% | ||
| $1M+625% | $138K-97.4% | $5.31M+2,726% | $188K-91.6% | $2.24M— | ||
| $2.08M-42.0% | $3.59M-84.3% | $22.93M-27.9% | $31.8M-27.2% | $43.65M+14.6% | ||
| $38.89M-61.1% | $99.94M+15.5% | $86.55M+26.1% | $68.63M+68.4% | $40.76M-95.8% | ||
| $29.4M-2.1% | $30.02M+101% | $14.93M-59.7% | $37.03M-10.6% | $41.43M-16.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Sarepta Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.